<DOC>
	<DOCNO>NCT01870999</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , efficacy pharmacokinetics aripiprazole intramuscular ( IM ) depot multiple dos every 4 week adult patient schizophrenia .</brief_summary>
	<brief_title>A Multiple Dose Safety , Tolerability Pharmacokinetics Study Adult Patients With Schizophrenia Following Administration Aripiprazole IM Depot</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>diagnosis schizophrenia define Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) criteria good physical health determine normal medical history , clinical laboratory result , electrocardiogram ( ECGs ) physical examination ability provide inform consent and/or consent legally acceptable representation body mass index ( BMI ) 18 35 kg/m^2 sexually active male female childbearing potential practicing double barrier birth control abstinent study plus 30 day female 90 day male follow last dose medication history drug alcohol abuse within 6 month and/or positive urine drug screen participant consume alcohol beverage routinely participant consume alcohol beverage screen period use antipsychotic medication , prohibit psychotropic medication , cytochrome P450 2D6 ( CYP2D6 ) cytochrome P450 3A4 ( CYP3A4 ) inhibitor CYP3A4 inducer within 14 day use prescription medication unless approve Medical Monitor Study Director history current hepatitis carrier HBsAg ( Hepatitis B surface antigen ) and/or Hepatitis C Virus antibody ( antiHCV ) females pregnant lactate participant participate clinical trial involve psychotropic medication within one month prior enrollment ; participant participate previous IM Depot study within last 1 year ; patient previously enrol receive study medication aripiprazole IM Depot clinical trial donation blood plasma blood bank clinical study ( except screen visit ) within 30 day prior enrollment major surgery within 30 day prior enrollment blood transfusion within 30 day prior enrollment evidence organ dysfunction clinically significant deviation normal physical , electrocardiographic , clinical laboratory examination patient represent significant risk commit suicide base history patient currently acute relapse patient Axis I ( DSMIV ) diagnosis schizoaffective bipolar disorder patient consider treatmentresistant antipsychotic medication patient history neuroleptic malignant syndrome sound medical reason determine clinical investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>